Supernus Pharmaceuticals Inc (SUPN) reported quarterly earnings results on Tuesday, May-3-2016. The company reported $0.08 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $0.09. The company posted revenue of $43.00 million in the period, compared to analysts expectations of $45.32 million. The company’s revenue was up 53.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS.
Many Wall Street Analysts have commented on Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals Inc was Upgraded by Jefferies to ” Buy” on Feb 8, 2016.
Supernus Pharmaceuticals Inc closed down -0.29 points or -1.69% at $16.87 with 5,64,186 shares getting traded on Monday. Post opening the session at $17.16, the shares hit an intraday low of $16.34 and an intraday high of $17.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 12, 2016, Padmanabh P. Bhatt (Sr. VP of IP, CSO) sold 30,762 shares at $16.49 per share price. According to the SEC, on Dec 8, 2015, M James Barrett (director) sold 212,970 shares at $14.56 per share price. On Jul 29, 2015, Stefan K.f. Schwabe (Executive Vice President R&D) sold 2,350 shares at $21.20 per share price, according to the Form-4 filing with the securities and exchange commission.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.